Supplemental figures

Phosphosulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: Enhanced efficacy and mitochondria targeting by its formulation in solid lipid

nanoparticles

0

200

400

PS PS sulfone Sulindac S. sulfone S. sulfide

Tu

mo

r d

rug

lev

el

pm

ole

/mg

pro

tein

Xenograft

Lung

Liver

Small intestine

Suppl.Fig.1 Drug level of PS and its metabolites in four organs after treated with PS via po.

S. sulfide

P=0.038

0%

15%

30%

45%

0 20 40 60 80 100

S. sulfideP=0.009

0%

20%

40%

60%

0 20 40 60 80 100

Sulindac

P = 0.041

0%

15%

30%

45%

0 100 200 300 400 500

Sulindac

P = 0.0001

0%

20%

40%

60%

0 100 200 300 400 500

S. sulfone

P=0.129

0%

15%

30%

45%

0 50 100 150 200

S. sulfone

P=0.017

0%

20%

40%

60%

0 50 100 150 200

TU

NE

L (

+)%

C

ell

Ki-

67

(+

)% C

ell

Drug level, pmole/mg protein

Suppl.Fig.2 Correlation between tumor drug level and Ki-67 or TUNEL positive cell ratio.